Our follow-up study on IgG4 in blood and saliva after 4 x COVID-19 mRNA vaccines is out on eBioMedicine 🧪 1)🧵So how does IgG4 influence responses to Omicron (XBB.1.5 and JN.1) and Sarbecoviruses (from bats, pangolins)? What epitopes are being targeted? authors.elsevier.com/sd/article/S...

Our paper exploring the effects of solid tumor malignancy-associated inflammation upon COVID-19 vaccine-induced antibodies is finally live! We show that while dysregulated inflammation impairs neutralization, variant cross-reactive Fc effector functions remain robust. www.nature.com/articles/s41...

In another preprint from the @brianhie.bsky.social Lab and @synbiogaolab.bsky.social, they introduce Germinal, a generative AI system for de novo antibody design. Germinal produces functional nanobodies in just dozens of tests, making custom antibody design more accessible than ever before.

In new study led by @ckikawa.bsky.social, we provide near real-time data on human neutralizing antibody landscape to influenza by measuring ~26,000 titers to >100 recent viral strains Data can inform vaccine selection & evolutionary/epidemiological modeling www.biorxiv.org/content/10.1...

🎉 Thrilled to share our newest paper and my first one in the Valkenburg lab @thedohertyinst.bsky.social published in @natcomms.nature.com: SARS-CoV-2 antibody responses in children exhibit higher FcR engagement and avidity than in adults doi.org/10.1038/s414... 👇1/5

The labs of Krammer, @wchnicholas.bsky.social, Ellebedy et al. identify a neuraminidase-targeting human monoclonal antibody (mAb-297) induced by seasonal #influenza vaccination that broadly protects against multiple influenza A & B strains, incl. avian #H5N1. rupress.org/jem/article/...

Nice summary and discussion about our recent IgG4 publication that just came out on #scienceadvances from @amywchung.bsky.social lab (kudos to our PhD candidate Carissa Aurelia 👩‍🔬🎉) Glad it has answered some technical questions and raised more for future work/discussion 🧐🔬🧪